Inflammatory Bowel Disease
Conditions
Keywords
Inflammatory Bowel Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Psoriasis, Pregnant women exposed to infliximab
Brief summary
The purpose of this study is collection and analysis of information pertaining to pregnancy outcomes in women exposed to infliximab during pregnancy, relative to the background risk in similar but non-biologic exposed patients; and information pertaining to health status, during the first year following delivery, of infants born to women following prenatal exposure to infliximab and their unexposed counterparts.
Detailed description
This registry will analyze birth outcomes data from Medical Birth Registers on approximately 370 women who have become pregnant and have been exposed to infliximab with the diseases of interest: Inflammatory Bowel Disease (Crohn's Disease \[CD\] and Ulcerative Colitis \[UC\]), Rheumatoid Arthritis \[RA\], Psoriatic Arthritis \[PsA\], Ankylosing Spondylitis \[AS\], and Psoriasis (Pso) as well as all women with the same diseases who have not been exposed to infliximab. Demographics and information related to the diseases of interest, past medical history, infliximab exposure during pregnancy (and up to 3 months prior to conception), use of other medications, and pregnancy outcomes information and infant birth information will be collected from the Swedish national health registries (a. Swedish Medical Birth Register \[SMBR\] b. Swedish Prescribed Drug Register c. Swedish Patient Register \[PAR\]), Danish national health registries (a. Danish Medical Birth Register \[DMBR\] b. Danish Register of Medicinal Product Statistics c. Danish National Patient Registry), and Finnish national health registries (a. Finnish Medical Birth Register \[FMBR\] b. Finnish Register on Prescribed Medicine c. Finnish National Care Register for Health Care Institutions \[HILMO\] d. Finnish Register on Congenital Malformations) during the study period. The health status of infants born to these women will be followed for 1 year after birth. During the 1-year follow-up period, information related to hospitalizations and antibiotic use will be obtained. No study medications will be administered in this registry. Treatments are as prescribed by the physician on the basis of usual clinical practice.
Interventions
OTHERNo intervention
This is an observational study. Patients receiving infliximab or anti-TNF as per the prescribing information will be observed.
Sponsors
Merck Sharp & Dohme LLC
Janssen Biotech, Inc.
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Healthy volunteers
Yes
Inclusion criteria
* Study patients must meet the following criteria: Women of childbearing age with birth outcomes recorded in either the Swedish Medical Birth Register (SMBR), Finnish Medical Birth Register (FMBR) or in the Danish Medical Birth Register (DMBR) who have confirmed diagnosis of Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or psoriasis and documented exposure to infliximab during pregnancy and infants born to these women * Control patients must meet the following criteria: Women of childbearing age with birth outcomes recorded in either the SMBR, FMBR or DMBR who have confirmed diagnosis of Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or psoriasis, and no exposure to biologics during pregnancy and infants born to these women
Exclusion criteria
* Information for women who do not have a documented history of the diseases of interest but whose birth outcomes are included in the SMBR, FMBR or DMBR during the study period and the infants of these women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of fetal death observed in pregnant women exposed and not exposed to infliximab | 5 years | — |
| Number of normal live birth observed in pregnant women exposed and not exposed to infliximab | 5 years | — |
| Number of abnormal live birth observed in pregnant women exposed and not exposed to infliximab | 5 years | Abnormal live birth will be considered if the birth outcome is preterm birth, small for gestational age/intrauterine growth retardation, malformations, or perinatal morbidity. |
| Number of fetal death observed in pregnant women with disease entity of interest exposed and not exposed to infliximab | 5 years | — |
| Number of normal live birth observed in pregnant women with disease entity of interest exposed and not exposed to infliximab | 5 years | — |
| Number of abnormal live birth observed in pregnant women with disease entity of interest exposed and not exposed to infliximab | 5 years | Abnormal live birth will be considered if the birth outcome is preterm birth, small for gestational age/intrauterine growth retardation, malformations, or perinatal morbidity. |
Secondary
| Measure | Time frame |
|---|---|
| Antibiotic use and hospital care during the first year after birth for infliximab exposed and non-exposed infants | 5 years |
Outcome results
None listed